Home
Senior Advisors to VIC From left to right: Jeffrey A. Gelfand, MD – Clinical Professor of Medicine, HMS and Senior Advisor to VIC; John T. Potts Jr, MD – Director of Research & Physician-in-Chief Emeritus, MGH; Michael V. Callahan, MD, DTM & HMSPH- Director of Translation Research at VIC.

Senior Advisors to VIC From left to right: Jeffrey A. Gelfand, MD – Clinical Professor of Medicine, HMS and Senior Advisor to VIC; John T. Potts Jr, MD – Director of Research & Physician-in-Chief Emeritus, MGH; Michael V. Callahan, MD, DTM & HMSPH- Director of Translation Research at VIC.

Vaccine and Immunotherapy Center Retreat Symposium

VIC had its second, successful annual retreat on January 19, 2017. The theme of the morning Symposium for VIC lab members and special guests was: “Anticipating Clinical Transition: Positioning Your Project for the Transition from Bench to Bedside”.

Each of the guest speakers gave fascinating, and valuable, insight into their experience of Translational Medicine.

Bruce Burnett, PhD is the Director of Regulatory Affairs at the Duke Translational Medicine Institute and also the Acting Director of the NIH Office of Research Support and Compliance. He spoke on: “Early Steps to Prepare Your Translational Project for Regulatory Clarity and Success”. He highlighted informational resources from the FDA and elsewhere that can inform translational science.

Frances Toneguzzo, PhD is the Executive Vice President of New Product Planning and Strategy and NantKwest and spoke on: “Bridging Laboratory Models to IND” using an example from her experience in industry and the steps and pitfalls involved.

Michael Callahan, MD, DTM&H, MSPH is the Director of Translation at VIC and gave a fast paced presentation on:”‘That Will Never be a Clinical Product’: Refining your Translational Concept to Avoid the Death Sentence”. VIC lab members were wide eyed after his presentation and admired his global knowledge as a result of his visits to areas in need of new vaccinations for Infectious Disease outbreaks.

Katrina Armstrong, MD is the Physician in Chief of the Department of Medicine at MGH and joined us to lend her support to the mission of the Vaccine and Immunotherapy Center and spoke on the importance of new models of innovation and making the results more broadly affordable.

The session ended with lunch and a chance for the VIC members to mingle with visitors and to take advantage of further discussions with our guest speakers.

In the afternoon, VIC senior scientists presented their applications for VIC seed funding to a grant review panel: Bruce Burnett, PhD Director of Regulatory Affairs at the Duke Translational Medicine Institute and  Acting Director of the NIH Office of Research Support and Compliance; Christiana Iyasere MD, MGH and the co-chair of the Department of Medicine’s Medicine Innovation Program: Robert Sackstein, MD, PhD, Professor Harvard Medical School and Director of the Program o Excellence in Glycosciences at BWH. The reviewers appreciated the level of innovative ideas, posed probing questions and offered valuable feedback. Their time and commitment to the process was greatly appreciated by scientists and management at VIC.